IP Library Granted Patent US 11,957,762
Granted Patent B2
US 11,957,762 · App. 15/577,998 · Granted Apr 16, 2024

Immune tolerant and non-immune tolerant elastin-like recombinant peptides and methods of use

Inventors: Mingnan Chen (Salt Lake City, UT); Hyung Jin Cho (Salt Lake City, UT); Peng Wang (Salt Lake City, UT); Shuyun Dong (Salt Lake City, UT); Peng Zhao (Salt Lake City, UT)
Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
A61K47/6435A61K31/337A61K31/35A61K39/0005A61K47/64A61P35/00A61P35/04C07K14/77C07K14/78A61K38/00A61K2039/6031C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,957,762
App. No.
15/577,998
Granted
Apr 16, 2024
Kind
B2
Abstract

Disclosed herein, are recombinant polypeptides comprising one or more homologous amino acid repeats; and, non-immunogenic bioconjugates comprising recombinant polypeptides comprising one or more homologous amino acid repeats and one or more therapeutic agents. Also, disclosed herein are pharmaceutical compositions including the recombinant polypeptides; and methods of administering the recombinant polypeptides to patients for the treatment of cancer or infections.

Claims (15)

1. A recombinant polypeptide comprising an homologous amino acid repeat sequence, wherein the homologous amino acid repeat sequence is Gly-Val-Leu-Pro-Gly-Val-Gly (SEQ ID NO: 1: iTEP A ), wherein the homologous amino acid repeat sequence is reiterated linearly.

2. A recombinant polypeptide comprising

(SEQ ID NO: 23)

Gly-(Gly-Val-Leu-Pro-Gly-Val-Gly) 28 -Gly-Gly;

(SEQ ID NO: 24)

Gly-(Gly-Ala-Gly-Val-Pro-Gly) 70 -Gly-Gly;

(SEQ ID NO: 25)

Gly-(Val-Pro-Gly-Phe-Gly-Ala-Gly-Ala-Gly) 21 -Gly-

Gly; or

(SEQ ID NO: 26)

Gly-(Val-Pro-Gly-Leu-Gly-Ala-Gly-Ala-Gly) 96 -Gly-

Gly.

3. The recombinant polypeptide of claim 1 , further comprising two or more of the homologous amino acid repeat sequences reiterated linearly.

4. A pharmaceutical composition comprising the recombinant polypeptide of claim 1 and a pharmaceutically acceptable carrier.

5. A pharmaceutical composition comprising the recombinant polypeptide of claim 2 and a pharmaceutically acceptable carrier.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 1, 2018
From: CHEN, MINGNAN; CHO, HYUNG JIN; WANG, PENG; DONG, SHUYUN; ZHAO, PENG
To: UNIVERSITY OF UTAH
Reel/Frame 046521/0781 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 1, 2018
From: UNIVERSITY OF UTAH
To: UNIVERSITY OF UTAH RESEARCH FOUNDATION
Reel/Frame 046521/0828 →
CONFIRMATORY LICENSE Recorded Feb 14, 2018
From: UNIVERSITY OF UTAH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 045331/0620 →
Continuity (3)
Provisional Application 62309113 · Mar 16, 2016
Provisional Application 62230160 · May 29, 2015
Related Publication 20180289830A1 · Oct 11, 2018